Key clinical point: Patients with moderate-to-severe atopic dermatitis (AD) who did not achieve Investigator's Global Assessment (IGA) 0/1 response with abrocitinib at week 12, still achieved clinically meaningful improvements in AD severity, itch, and quality of life.
Major finding: At week 12, a higher proportion of IGA nonresponders receiving 200 and 100 mg abrocitinib vs placebo achieved ≥ 75% improvement in the Eczema Area and Severity Index (41.0% and 27.0% vs 9.4%, respectively), ≥4-point improvement in itch (42.8% and 35.2% vs 18.2%, respectively), and ≥4-point improvement in Dermatology Life Quality Index (67.6% and 75.0% vs 49.5%, respectively) scores.
Study details: Findings are from a post hoc analysis of 1 phase 2b and 2 phase 3 ( JADE Mono-1 and JADE Mono-2 ) trials including 548 patients with moderate-to-severe AD who were randomly assigned to receive abrocitinib (200 or 100 mg) or placebo and did not achieve IGA 0/1 response.
Disclosures: This study was funded by Pfizer Inc. Five authors declared being current or former employees and shareholders of Pfizer. The other authors reported ties with various sources, including Pfizer.
Source: Blauvelt A et al. Abrocitinib monotherapy in Investigator’s Global Assessment nonresponders: Improvement in signs and symptoms of atopic dermatitis and quality of life. J Dermatolog Treat. 2022 (Jul 6). Doi: 10.1080/09546634.2022.2059053